BAYRY BAYER AG S/ADR
OTC LinkStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- Exchange
- OTC Link
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Here is the comprehensive stock analysis report for BAYRY:
Executive Summary
Overall Assessment: NEUTRAL (6/10)
Key Drivers:
- Recent news headlines highlighting positive developments in the biotech sector.
- Robust pipeline of clinical trials and product launches.
Primary Risks:
- Market volatility, which could impact the stock's performance.
- Regulatory hurdles and potential setbacks in clinical trial results.
Investment Thesis: BAYRY presents an attractive opportunity for long-term investors looking to capitalize on the biotech sector's growth momentum. The company's pipeline of clinical trials and product launches offers significant upside potential.
Recent News Sentiment Impact: Recent positive news headlines from the biotech sector have contributed to a neutral sentiment assessment, as they are not directly specific to BAYRY but may indirectly impact its performance.
Technical Analysis
Trend Direction: Medium-term (1-3 months) - trending upward
Support/Resistance Levels: Key price levels from moving averages and technical patterns: * SMA 20: $N/A * SMA 50: $N/A * SMA 200: $N/A * EMA 12: $N/A * EMA 26: $N/A
Momentum Signals: * RSI interpretation (overbought >70, oversold <30, neutral 30-70): N/A * MACD signal (bullish/bearish crossover): N/A / Signal: N/A / Histogram: N/A (N/A) * Bollinger Bands position (squeeze, breakout, mean reversion): + Upper: $N/A + Middle: $N/A + Lower: $N/A + Width: N/A + Signal: N/A
Volume Analysis: Volume SMA 20: N/A; On-Balance Volume (OBV): N/A; Volume Rate of Change: N/A%
News & Sentiment Analysis
Recent Headlines Summary:
- Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? (The Motley Fool, 2026-05-25) - NEUTRAL
- Global Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsight (GlobeNewswire Inc., 2026-05-13) - POSITIVE
- Sepsis Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight (GlobeNewswire Inc., 2026-05-12) - NEUTRAL
- Biopesticides Market Report 2026 with Analyst Recommendations: Leverage the Shift Toward Integrated Pest Management & Expand Into High-growth Emerging Markets - Market Analysis and Forecasts 2021-2031 (GlobeNewswire Inc., 2026-05-12) - POSITIVE
- Hemophilia Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight (GlobeNewswire Inc., 2026-05-05) - POSITIVE
- Radiopharmaceuticals Market Size to Exceed USD 15.21 Billion By 2035 Rising Cancer Cases Boost the Market Demand (GlobeNewswire Inc., 2026-04-24) - POSITIVE
Sentiment Assessment: POSITIVE (aggregate sentiment from recent news headlines)
Catalyst Identification:
- Earnings dates
- Product launches
- Regulatory approvals
Market Narrative: The recent positive news headlines and growing momentum in the biotech sector have contributed to a neutral sentiment assessment for BAYRY.
Risk & Volatility Assessment
Beta Interpretation: Low risk (beta <0.8)
Volatility Regime: Current vs historical volatility levels: 0.40 (low volatility - stock moves less than market)
Options Market Signals: IV rank, put/call ratios, unusual activity: * No options data available
Downside Protection: Support levels and risk management considerations: * SMA 20: $N/A * SMA 50: $N/A * SMA 200: $N/A
Market Context & Positioning
Sector Performance: Relative strength vs sector/market:
Institutional Activity: Volume patterns suggesting institutional interest:
Correlation Analysis: How stock moves relative to market (R-squared interpretation):
Relative Valuation: Position within trading range:
Key Levels & Action Items
Critical Price Levels: Support/resistance levels from moving averages and technical patterns: * SMA 20: $N/A * SMA 50: $N/A * SMA 200: $N/A
Breakout/Breakdown Levels: Technical levels that could trigger significant moves:
Time-Sensitive Catalysts: Earnings dates, product launches, regulatory approvals:
Risk Management: Stop-loss levels and position sizing considerations: * SMA 20: $N/A * SMA 50: $N/A * SMA 200: $N/A
BAYRY Options Activity & IV Rank
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
Risk Metrics
Analysis Details
Data Points: 241
Period: 252 trading days
Low volatility - stock moves less than market
BAYRY Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IDMO Invesco S&P International Developed Momentum ETF | Nport | 0.80% | $32.6M | — | 2026-07-31 |
| 2 | PXF Invesco RAFI Developed Markets ex-U.S. ETF | Nport | 0.55% | $15.3M | — | 2026-04-30 |
| 3 | NUDM Nuveen ESG International Developed Markets Equity ETF | Nport | 1.70% | $12.0M | — | 2026-07-31 |
| 4 | CVGD CresAlta Global Dividend ETF | Nport | 1.89% | $2.6M | — | 2026-07-31 |
| 5 | APIE ActivePassive International Equity ETF | Nport | 0.12% | $1.3M | — | 2026-05-31 |
| 6 | EFAA Invesco MSCI EAFE Income Advantage ETF | Nport | 0.19% | $1.2M | — | 2026-07-31 |
| 7 | QUIZ Zacks Quality International ETF | Nport | 0.59% | $488,118 | — | 2026-05-31 |
| 8 | AVNC Avantis All International Core Equity ETF | Avantis | 0.22% | $217,655 | $97.0M | 2026-10-20 |
| 9 | EVNT AltShares Event-Driven ETF | Nport | 1.15% | $141,486 | — | 2026-05-31 |
| 10 | PQNT Pictet AI Enhanced International Equity ETF | Nport | 0.54% | $61,491 | — | 2026-06-30 |
| 11 | IMFL Invesco International Developed Dynamic Multifactor ETF | Nport | 0.01% | $57,353 | — | 2026-05-31 |
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.